CA Patent

CA3177279A1 — Anti-psma antibody-exatecan analogue conjugate and medical use thereof

Assigned to Shanghai Hengrui Pharmaceutical Co Ltd · Expires 2021-09-30 · 5y expired

What this patent protects

Provided are an anti-PSMA antibody-Exatecan analogue conjugate and medical use thereof. Specifically, provided is an anti-PSMA antibody-drug conjugate represented by general formula (Pc-L-Y-D), wherein Pc is an anti-PSMA antibody or an antigen-binding fragment thereof.

USPTO Abstract

Provided are an anti-PSMA antibody-Exatecan analogue conjugate and medical use thereof. Specifically, provided is an anti-PSMA antibody-drug conjugate represented by general formula (Pc-L-Y-D), wherein Pc is an anti-PSMA antibody or an antigen-binding fragment thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3177279A1
Jurisdiction
CA
Classification
—
Expires
2021-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.